NovoCure Ltd (NASDAQ: NVCR) is 19.89% higher on its value in year-to-date trading and has touched a low of $10.87 and a high of $31.73 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The NVCR stock was last observed hovering at around $18.91 in the last trading session, with the day’s loss setting it -1.01%.
Currently trading at $17.90, the stock is -8.60% and -6.79% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.13 million and changing -5.34% at the moment leaves the stock 12.65% off its SMA200. NVCR registered -42.72% loss for a year compared to 6-month gain of 12.37%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -3.14% loss in the last 1 month and extending the period to 3 months gives it a -19.26%, and is -4.23% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.58% over the week and 6.79% over the month.
NovoCure Ltd (NVCR) has around 1453 employees, a market worth around $1.94B and $549.96M in sales. Profit margin for the company is -30.67%. Distance from 52-week low is 64.67% and -43.59% from its 52-week high. The company has generated returns on investments over the last 12 months (-16.27%).
The EPS is expected to grow by 29.89% this year.
NovoCure Ltd (NVCR) Top Institutional Holders
330.0 institutions hold shares in NovoCure Ltd (NVCR), with institutional investors hold 95.51% of the company’s shares. The shares outstanding are 107.08M, and float is at 97.42M with Short Float at 7.80%. Institutions hold 86.70% of the Float.
The top institutional shareholder in the company is FMR LLC with over 16.06 million shares valued at $$251.08 million. The investor’s holdings represent 15.099 of the NVCR Shares outstanding. As of 2024-03-31, the second largest holder is VANGUARD GROUP INC with 10.02 million shares valued at $$156.67 million to account for 9.4218 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 9.08 million shares representing 8.5387 and valued at over $$141.99 million, while CAPITAL INTERNATIONAL INVESTORS holds 8.3316 of the shares totaling 8.86 million with a market value of $$138.55 million.
NovoCure Ltd (NVCR) Insider Activity
The most recent transaction is an insider sale by Cordova Ashley,the company’sChief Financial Officer. SEC filings show that Cordova Ashley sold 688 shares of the company’s common stock on Aug 02 ’24 at a price of $20.14 per share for a total of $13857.0. Following the sale, the insider now owns 0.22 million shares.
NovoCure Ltd disclosed in a document filed with the SEC on Jun 04 ’24 that VERNON W ANTHONY (Director) sold a total of 964 shares of the company’s common stock. The trade occurred on Jun 04 ’24 and was made at $23.89 per share for $23033.0. Following the transaction, the insider now directly holds 0.16 million shares of the NVCR stock.
Still, SEC filings show that on Jun 04 ’24, Scannell Timothy J (Director) disposed off 964 shares at an average price of $23.89 for $23027.0. The insider now directly holds 2,964 shares of NovoCure Ltd (NVCR).
